Myriad Genetics, Inc.

Sera Prognostics, Inc.SERA · BiotechSalt Lake City, United States

68% matchPublic

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

Yourgene HealthBiotechUnited Kingdom

63% match

Yourgene Health was a UK molecular diagnostics company that developed and commercialized genomic testing technologies, with a focus on reproductive health and non-invasive prenatal testing, including the IONA test. It served clinical laboratories, healthcare providers, and diagnostic partners; the company was acquired by Novacyt in 2023.

Juno Diagnostics, Inc.Biotechnology & HealthcareUnited States

63% matchPrivate

Juno Diagnostics, Inc. operates a laboratory specializing in preimplantation genetic testing for patients undergoing fertility treatments and IVF. The company offers advanced genetic screenings to detect chromosomal abnormalities, single-gene disorders, and structural rearrangements in embryos.

GENE SOLUTIONS LLCBiotechVietnam

62% matchPrivate

Gene Solutions LLC provides AI-powered genetic testing and multi-dimensional genomics services focused on oncology and reproductive health. The company offers blood-based early cancer detection tests, tumor profiling, and minimal residual disease monitoring for patients and healthcare providers.

Orchid Health, Inc.HealthcareUnited States

61% matchPrivate

Orchid Health, Inc. provides whole-genome embryo screening services for individuals and couples undergoing in vitro fertilization (IVF). The company's testing evaluates embryos for genetic predispositions to thousands of conditions, including cancers, neurodevelopmental disorders, and heart defects, to help patients mitigate hereditary health risks.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.